Literature DB >> 31678033

Increased striatal dopamine in carriers of GBA mutations: compensation or epiphenomenon?

Nicolaas I Bohnen1, Roger L Albin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31678033      PMCID： PMC6924570          DOI： 10.1016/S1474-4422(19)30355-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  7 in total

1.  Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.

Authors:  Alex Iranzo; Francesc Valldeoriola; Francisco Lomeña; José Luis Molinuevo; Mónica Serradell; Manel Salamero; Albert Cot; Domènec Ros; Javier Pavía; Joan Santamaria; Eduardo Tolosa
Journal:  Lancet Neurol       Date:  2011-07-28       Impact factor: 44.182

2.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Authors:  John R Adams; Hinke van Netten; Michael Schulzer; Edwin Mak; Jessamyn Mckenzie; Audrey Strongosky; Vesna Sossi; Thomas J Ruth; Chong S Lee; Matthew Farrer; Thomas Gasser; Ryan J Uitti; Donald B Calne; Zbigniew K Wszolek; A Jon Stoessl
Journal:  Brain       Date:  2005-08-04       Impact factor: 13.501

3.  Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study.

Authors:  Seyed-Mohammad Fereshtehnejad; Chun Yao; Amelie Pelletier; Jacques Y Montplaisir; Jean-François Gagnon; Ronald B Postuma
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

4.  Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease.

Authors:  G A Graveland; R S Williams; M DiFiglia
Journal:  Science       Date:  1985-02-15       Impact factor: 47.728

Review 5.  GBA1-associated parkinsonism: new insights and therapeutic opportunities.

Authors:  Emory Ryan; Gurpreet Seehra; Pankaj Sharma; Ellen Sidransky
Journal:  Curr Opin Neurol       Date:  2019-08       Impact factor: 5.710

6.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Authors:  Tanya Simuni; Liz Uribe; Hyunkeun Ryan Cho; Chelsea Caspell-Garcia; Christopher S Coffey; Andrew Siderowf; John Q Trojanowski; Leslie M Shaw; John Seibyl; Andrew Singleton; Arthur W Toga; Doug Galasko; Tatiana Foroud; Duygu Tosun; Kathleen Poston; Daniel Weintraub; Brit Mollenhauer; Caroline M Tanner; Karl Kieburtz; Lana M Chahine; Alyssa Reimer; Samantha J Hutten; Susan Bressman; Kenneth Marek
Journal:  Lancet Neurol       Date:  2019-10-31       Impact factor: 44.182

7.  Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.

Authors:  James B Koprich; Tom H Johnston; Philippe Huot; M Gabriela Reyes; Maria Espinosa; Jonathan M Brotchie
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240
  7 in total
  1 in total

Review 1.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.